Genmab A/S (GMAB)
NASDAQ: GMAB · Real-Time Price · USD
27.89
+0.37 (1.34%)
At close: May 6, 2026, 4:00 PM EDT
28.15
+0.26 (0.93%)
Pre-market: May 7, 2026, 8:25 AM EDT
Genmab Market Cap
Genmab has a market cap or net worth of $17.09 billion as of May 7, 2026. Its market cap has increased by 27.35% in one year.
Market Cap
17.09B
Enterprise Value
20.80B
1-Year Change
27.35%
Ranking
Category
Stock Price
$27.89
Market Cap Chart
Since April 23, 2012, Genmab's market cap has increased from $420.50M to $17.09B, an increase of 3,963.15%. That is a compound annual growth rate of 30.18%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 6, 2026 | 17.92B | -9.40% |
| Dec 31, 2025 | 19.78B | 43.19% |
| Dec 31, 2024 | 13.81B | -34.35% |
| Dec 29, 2023 | 21.04B | -24.60% |
| Dec 30, 2022 | 27.90B | 7.47% |
| Dec 31, 2021 | 25.96B | -1.89% |
| Dec 31, 2020 | 26.46B | 84.27% |
| Dec 31, 2019 | 14.36B | 35.31% |
| Dec 31, 2018 | 10.61B | -0.44% |
| Dec 29, 2017 | 10.66B | -0.04% |
| Dec 30, 2016 | 10.66B | 23.74% |
| Dec 31, 2015 | 8.62B | 128.70% |
| Dec 31, 2014 | 3.77B | 49.72% |
| Dec 31, 2013 | 2.52B | 179.56% |
| Dec 31, 2012 | 900.30M | 114.10% |
| Apr 23, 2012 | 420.50M | - |
View and export this data all the way back to 2012. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Roivant Sciences | 20.30B |
| Incyte | 19.41B |
| Moderna | 18.77B |
| Ascendis Pharma | 14.13B |
| BridgeBio Pharma | 13.51B |
| Summit Therapeutics | 13.18B |
| Jazz Pharmaceuticals | 12.81B |
| Ionis Pharmaceuticals | 12.47B |